A biotech company based in Spain, RidNova Pharmaceuticals, has announced advancements in formulation development that enable the delivery of larger molecules directly to the pulmonary system. Utilizing nanotechnology, the company is focusing on therapies involving proteins, peptides, and other biologics aimed at the lung surface.
Founder and CEO Devendra Ridhurkar, PhD, will address the potential and challenges of nanoparticle development at the upcoming 2026 Bioprocessing Summit Europe. Ridhurkar emphasizes the advantages of respiratory delivery due to the lungs’ extensive vascularization and rapid absorption capabilities, which are ideal for administering newer therapies based on peptides and nucleic acids.
Among the therapies in development are innovative treatments for asthma and chronic obstructive pulmonary disease (COPD), alongside vaccines for respiratory illnesses. RidNova aims to commercialize these formulations by 2026 or 2027, although they face hurdles such as stabilizing molecules initially designed for liquid injection and navigating regulatory complexities related to safety assessments and clinical trial design.
The formulations incorporate polymer-based nanoparticles and a liposomal drug release system, necessitating spray drying for enhanced stability. Additionally, the company is focused on minimizing molecule size for optimal lung absorption while ensuring that the formulations remain intact against chemical degradation in the lung environment.
Get started today with Solo access →
